Overview

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
Phase:
Phase 2
Details
Lead Sponsor:
Mylan Inc.
Theravance Biopharma R & D, Inc.
Collaborator:
Theravance Biopharma